2026年2月24日， 美敦力 Medtronic 旗下糖尿病业务MiniMed 更新美国SEC招股书，正式披露 IPO定价 区间为25–28美元/股 ，拟发行2800万股，募资规模最高可达7.84亿美元，对应整体估值约78.6亿美元。 公司计划以"MMED"为代码登陆纳斯达克，并在IPO完成后通过后续split-off实现与母公司的完全剥离。 （定价="可比公司估值参考 + 当前市场情绪 + 路演需求" 的谈判结果。 从财务表现看，这一业务正处于一个典型的 "增长修复期" 。2025财年收入达到 27.5亿美元， 同比 增长 10.7%； 2026财年上半年收入 继续增长13.8%， 同时亏损逐步收窄。也就是说，MiniMed正在从此前的 增长承压阶段，逐步过渡到盈利能力改善阶段。 这正是资本市场窗口期的典型特征：增长恢复、亏损收敛、路径清晰。 # 从设备到系统：技术路径已经发生根本变化 目标是既能顺利募资7.84亿（高价端），又不让新投资者觉得太贵，同时为美敦力后续完全剥离创造良好开局。最终成交价 要等3月初定价日才知道，通常会在区间内或略高，如果需求火爆的话。 ） 这一动作意味着，始于2024年的分拆计 ...

Core Viewpoint - Medtronic's MiniMed Group has filed for an IPO with the SEC, marking a significant structural capital adjustment for the company. This carve-out IPO reflects a proactive restructuring around differing growth trajectories rather than a simple asset divestiture [1][2]. Timeline of the Carve-Out Event - The decision for MiniMed's independent listing was not made overnight but followed a gradual signaling and phased approach. This timeline helps to understand the background and pace of the IPO [2]. - Early 2024: Medtronic's management first indicated an evaluation of the long-term positioning of the diabetes business within the group structure, highlighting significant differences in business model, growth pace, and capital attributes compared to other high-value device segments [3]. - Mid-2024: Medtronic confirmed its intention to pursue a carve-out strategy for the diabetes business, positioning MiniMed for potential independent listing [4]. - Late 2024: MiniMed officially submitted its IPO registration statement to the SEC, marking the transition from strategic planning to actual execution [4]. MiniMed's Positioning - MiniMed is not a poorly performing segment; rather, it operates under a different growth logic compared to Medtronic's overall performance, which has shown a steady but slowing growth rate [5][8]. - The growth model for MiniMed is based on patient scale, usage duration, consumable repurchase, and system stickiness, which are typical characteristics of chronic disease management businesses [9]. Reasons for the Carve-Out - The financial presentation of MiniMed within Medtronic's consolidated statements posed challenges, as its stable but lower growth rate could dilute the overall growth elasticity of the group [10][12]. - The carve-out allows for clearer financial communication and enhances the capital market's ability to evaluate MiniMed based on its long-term patient value rather than annual revenue fluctuations [12][19]. Product and Technology Strategy - MiniMed is not just a single device company; it has developed a comprehensive solution around insulin delivery and glucose monitoring, including the automated insulin delivery system (AID) [13][15]. - The technology strategy focuses on reliability, stability, and long-term user experience rather than aggressive disruptive innovation, which is advantageous in chronic disease management [16]. Implications for Medtronic - The separation of MiniMed does not indicate Medtronic's exit from the diabetes sector but rather aims to reduce structural friction and clarify the growth narratives of different business segments [17]. - The carve-out is a rational choice for a mature medical device company entering a phase of stock competition, allowing for better alignment of business growth stages [17][20].